Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 5, Issue 3, 1998, Pages 187-192

  Wong, V S ^a   Hughes, V ^b   Trull, A ^b   Wight, D G D ^b   Petrik, J ^b   Alexander, G J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Fibrosis; Hepatitis C; Hyaluronic acid

Indexed keywords

HYALURONIC ACID; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FIBROGENESIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; FEMALE; GLUTATHIONE TRANSFERASE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 0031876788     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00100.x     Document Type: Article

References (26)

1. Gressner AM. Cellular sources of non-collagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 1990; 10: 30-46.
2. Gressner AM. Connective tissue parameters in serum for diagnosis and follow-up of liver fibrosis. Ann Clin Lab Sci 1987; 24: 283-292.
3. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991; 24: 219-239.
4. Fraser J, Laurent T, Pertoft N, Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronan injected intravenously in the rabbit. Biochem J 1981; 200: 415-124.
5. Erickson AL, Houghton M, Choo QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993; 151: 4189-4199.
6. Murata K, Ochiai Y, Akashio K. Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. Gastroenterology 1985; 89: 1248-1257.
7. Engstorm-Laurent A, Loof L, Nyberg A, Schroder T. Increased serum levels of hyaluronidate in liver disease. Hepatology 1985; 5: 638-642.
8. Freborug T, Delpech B, Bercoff E et al. Serum hyaluronidate in liver diseases: study by enzymoimmunological assay. Hepatology 1986; 6: 3929-3995.
9. Nyberg A, Engstrome-Laurent A, Loof L. Serum hyaluronidate in primary biliary cirrhosis: a biochemical marker for progressive liver damage. Hepatology 1988; 8: 152-156.
10. Tremolada F, Casarin C, Alberti A et al. Long-term followup of non-A, non-B (type C) post-transfusion hepatitis C. J Hepatol 1992; 16: 273-281.
11. Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993; 34: S13-S16.
12. Alberti A, Morsica G, Cavalletto D, Noventa F, Pontisso P. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-698.
13. Wong V, Caronia S, Wight D, Britton P, Palmer C, Alexander G. Liver biopsy is essential in the management of patients with chronic hepatitis C virus infection. Gut 1995; 36: A949-A950.
14. Healey C, Chapman R, Fleming K. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995; 37: 274-278.
15. Irving WL, Neal KR, Underwood JCE et al. Chronic hepatitis in United Kingdom blood donors infected with hepatitis C virus. Br Med J 1994; 308: 695-696.
16. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-238.
17. Ishak K, Baptista A, Biachi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 2: 696-699.
18. Wong VS, Wight DGD, Palmer CR, Alexander GJM. The interrelationship of fibrosis to other inflammatory features of hepatocellular damage in chronic HCV infection. J Clin Pathol 1996; 49: 1-6.
19. Gardner J, Altman DG, Confidence interval rather than p-value: estimation rather than hypothesis testing. Br Med J 1986; 292: 746-750.
20. Gibson P, Fraser J, Brown T et al. Haemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology 1992; 15: 1054-1059.
21. Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary fibrosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388-393.
22. Beukers R, van Zanten RAA, Schalm SW. Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis. J Hepatol 1992; 14: 22-29.
23. McCullogh AJ, Stassen WN, Wiesener RH, Czaja AJ. Serum type III procollagen peptide concentration in severe chronic active hepatitis: relationship to cirrhosis and liver disease. Hepatology 1987; 7: 49-54.
24. Fraser J, Engstrom-Laurent A, Nyberg A, Laurent T. Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. J Lab Clin Med 1986; 107: 79-85.
25. Lindqvist U, Groth T, Loof L. Hellsing K. A hyaluronan loading test applied to patients with liver and joint diseases. Clin Chim Acta 1992; 210: 119-132.
26. Deaciuc IV, Bagby CH, Skrepnik, Spitzer JJ. Gram-negative bacterial lipopolysaccharide impairs hyaluronan clearance in vitro and its uptake by the isolated, perfused rat liver. Hepatology 1993; 18: 173-178.